Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.

Stanam A, Gibson-Corley KN, Love-Homan L, Ihejirika N, Simons AL.

Oncotarget. 2016 Nov 15;7(46):76087-76100. doi: 10.18632/oncotarget.12590.

2.

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.

Sobhakumari A, Orcutt KP, Love-Homan L, Kowalski CE, Parsons AD, Knudson CM, Simons AL.

Oncol Res. 2016;24(1):55-64. doi: 10.3727/096504016X14586627440192.

3.

Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.

Stanam A, Love-Homan L, Joseph TS, Espinosa-Cotton M, Simons AL.

Mol Oncol. 2015 Aug;9(7):1371-83. doi: 10.1016/j.molonc.2015.03.008. Epub 2015 Apr 2.

4.

MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

Koch AT, Love-Homan L, Espinosa-Cotton M, Stanam A, Simons AL.

Cancer Res. 2015 Apr 15;75(8):1657-67. doi: 10.1158/0008-5472.CAN-14-2061. Epub 2015 Feb 20.

5.

EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.

Fletcher EV, Love-Homan L, Sobhakumari A, Feddersen CR, Koch AT, Goel A, Simons AL.

Mol Cancer Res. 2013 Dec;11(12):1574-84. doi: 10.1158/1541-7786.MCR-13-0187. Epub 2013 Sep 18.

6.

NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.

Sobhakumari A, Schickling BM, Love-Homan L, Raeburn A, Fletcher EV, Case AJ, Domann FE, Miller FJ Jr, Simons AL.

Toxicol Appl Pharmacol. 2013 Nov 1;272(3):736-45. doi: 10.1016/j.taap.2013.07.013. Epub 2013 Jul 31.

7.

Attenuation of Leishmania infantum chagasi metacyclic promastigotes by sterol depletion.

Yao C, Gaur Dixit U, Barker JH, Teesch LM, Love-Homan L, Donelson JE, Wilson ME.

Infect Immun. 2013 Jul;81(7):2507-17. doi: 10.1128/IAI.00214-13. Epub 2013 Apr 29.

8.

Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.

Sobhakumari A, Love-Homan L, Fletcher EV, Martin SM, Parsons AD, Spitz DR, Knudson CM, Simons AL.

PLoS One. 2012;7(10):e48175. doi: 10.1371/journal.pone.0048175. Epub 2012 Oct 31.

9.

Leukocytes infiltrate the skin and draining lymph nodes in response to the protozoan Leishmania infantum chagasi.

Thalhofer CJ, Chen Y, Sudan B, Love-Homan L, Wilson ME.

Infect Immun. 2011 Jan;79(1):108-17. doi: 10.1128/IAI.00338-10. Epub 2010 Oct 11.

10.

In vivo imaging of transgenic Leishmania parasites in a live host.

Thalhofer CJ, Graff JW, Love-Homan L, Hickerson SM, Craft N, Beverley SM, Wilson ME.

J Vis Exp. 2010 Jul 27;(41). pii: 1980. doi: 10.3791/1980.

11.

Evaluation of a novel photoactive and biotinylated dehydroepiandrosterone analog.

Liu D, O'Leary B, Iruthayanathan M, Love-Homan L, Perez-Hernandez N, Olivo HF, Dillon JS.

Mol Cell Endocrinol. 2010 Oct 26;328(1-2):56-62. doi: 10.1016/j.mce.2010.07.002. Epub 2010 Jul 27.

PMID:
20670672
12.

Dehydroepiandrosterone inhibits intracellular calcium release in beta-cells by a plasma membrane-dependent mechanism.

Liu D, Ren M, Bing X, Stotts C, Deorah S, Love-Homan L, Dillon JS.

Steroids. 2006 Aug;71(8):691-9. Epub 2006 May 24.

PMID:
16725167
13.

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.

Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, Vogel JC.

Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6970-5.

14.

CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming.

Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert PH, Krieg AM, Siegrist CA.

J Immunol. 1999 Feb 1;162(3):1611-7.

15.

Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs.

Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12631-6.

16.

CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge.

Krieg AM, Love-Homan L, Yi AK, Harty JT.

J Immunol. 1998 Sep 1;161(5):2428-34.

17.

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.

Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM.

Vaccine. 1998 Jul;16(11-12):1216-24.

PMID:
9682382
18.

Generation of a human monoclonal antibody to hepatitis C virus, JRA1 by activation of peripheral blood lymphocytes and hypo-osmolar electrofusion.

Zimmermann U, Love-Homan L, Gessner P, Clark D, Klöck G, Johlin FC, Neil GA.

Hum Antibodies Hybridomas. 1995;6(2):77-80.

PMID:
7492755
19.

Induction of hepatic pathology in SCID-Hu mice engrafted with peripheral blood lymphocytes of patients with Schistosomiasis japonica.

Kresina TF, Wisnewski A, Love-Homan L, Ramirez B, Neil GA.

J Infect Dis. 1994 Sep;170(3):733-6.

PMID:
8077739
21.

Adhesion molecules on murine brain microvascular endothelial cells: expression and regulation of ICAM-1 and Lgp 55.

Fabry Z, Waldschmidt MM, Hendrickson D, Keiner J, Love-Homan L, Takei F, Hart MN.

J Neuroimmunol. 1992 Jan;36(1):1-11.

PMID:
1346536
22.

Adhesion of splenocytes to brain microvascular endothelium in the BALB/c and SJL/j mouse systems.

Waldschmidt MM, Fabry Z, Keiner J, Love-Homan L, Hart MN.

J Neuroimmunol. 1991 Dec;35(1-3):191-200.

PMID:
1683352

Supplemental Content

Loading ...
Support Center